NDC 0310-0088 – Daliresp
Roflumilast 250 ug/1 · Tablet · Oral
Product NDC0310-0088
Product details
- Brand name
- Daliresp
- Generic name
- Roflumilast
- Labeler
- AstraZeneca Pharmaceuticals LP
- Dosage form
- Tablet
- Route
- Oral
- Marketing category
- NDA · NDA022522
- Marketed since
- July 1, 2015
- Listing expires
- December 31, 2026
- Pharmacologic class
- Phosphodiesterase 4 Inhibitor
Active ingredients
- Roflumilast 250 ug/1
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 0310-0088-28 | 1 BLISTER PACK in 1 BOX, UNIT-DOSE (0310-0088-28) / 28 TABLET in 1 BLISTER PACK | Jan 23, 2018 |
| 0310-0088-39 | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (0310-0088-39) / 2 TABLET in 1 BLISTER PACK | Jan 23, 2018 |
Other Daliresp products
- 0310-0095 Roflumilast 500 ug/1 · Tablet · AstraZeneca Pharmaceuticals LP